{"title":"滥用 Ozempic 作为减肥药物的潜在威胁","authors":"Uzma Aslam, Sarah Mehboob","doi":"10.18203/issn.2454-2156.intjscirep20233563","DOIUrl":null,"url":null,"abstract":"The 387 million people around the globe are diagnosed with type 2 diabetes mellitus (T2DM). Previously used agents to treat T2DM posed adverse risks of hypoglycaemia and weight gain. Recently, Novo Nordisk, a pharmaceutical company, launched a new drug, Ozempic (Semaglutide), a glucagon-like peptide-1 receptor agonist (GLP-1 RA), which was approved by the US Food and Drug Administration on December 5, 2017. The numerous benefits of Ozempic makes it ideal for treatment of T2DM. Unfortunately, there is now an alarming shortage of Ozempic due to its misuse for weight loss.","PeriodicalId":14297,"journal":{"name":"International Journal of Scientific Reports","volume":"7 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Misuse of Ozempic as a drug choice for weight loss, a potential threat\",\"authors\":\"Uzma Aslam, Sarah Mehboob\",\"doi\":\"10.18203/issn.2454-2156.intjscirep20233563\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The 387 million people around the globe are diagnosed with type 2 diabetes mellitus (T2DM). Previously used agents to treat T2DM posed adverse risks of hypoglycaemia and weight gain. Recently, Novo Nordisk, a pharmaceutical company, launched a new drug, Ozempic (Semaglutide), a glucagon-like peptide-1 receptor agonist (GLP-1 RA), which was approved by the US Food and Drug Administration on December 5, 2017. The numerous benefits of Ozempic makes it ideal for treatment of T2DM. Unfortunately, there is now an alarming shortage of Ozempic due to its misuse for weight loss.\",\"PeriodicalId\":14297,\"journal\":{\"name\":\"International Journal of Scientific Reports\",\"volume\":\"7 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Scientific Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18203/issn.2454-2156.intjscirep20233563\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Scientific Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18203/issn.2454-2156.intjscirep20233563","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Misuse of Ozempic as a drug choice for weight loss, a potential threat
The 387 million people around the globe are diagnosed with type 2 diabetes mellitus (T2DM). Previously used agents to treat T2DM posed adverse risks of hypoglycaemia and weight gain. Recently, Novo Nordisk, a pharmaceutical company, launched a new drug, Ozempic (Semaglutide), a glucagon-like peptide-1 receptor agonist (GLP-1 RA), which was approved by the US Food and Drug Administration on December 5, 2017. The numerous benefits of Ozempic makes it ideal for treatment of T2DM. Unfortunately, there is now an alarming shortage of Ozempic due to its misuse for weight loss.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
